Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Mitsubishi Tanabe Going Digital to Shed Drug Discovery and Sales Outlays: President
August 21, 2018
- I/O in Lung Cancer - 2: After MYSTIC Flop, AstraZeneca’s Imfinzi Makes Comeback with Stage III NSCLC Nod
August 20, 2018
- Roche Diagnostics’ EGFR Mutations Test Kit Approved for Determining 1st Line Treatment of Tagrisso
August 20, 2018
- Solasia Licenses PTCL Treatment to Columbia Firm in Latin America
August 20, 2018
- Taiho Files Lonsurf for Gastric Cancer in Japan
August 20, 2018
- FDA Approves Lenvima for 1st-Line Treatment of Liver Cancer
August 17, 2018
- Maviret Top-Seller Drug in Japan in July: Encise Snapshot
August 17, 2018
- Nesp “Biosame” Could Hit Market as Early as December
August 17, 2018
- Japanese Enrollment Begins for PII Venglustat Study for Gaucher’s Disease: Sanofi Genzyme
August 16, 2018
- Daiichi Sankyo Espha Likely to Roll Out Urief, Iressa Authorized Generics: December Listing
August 16, 2018
- FunPep Begins Joint Research with Osaka Univ. to Boost Development of Antibody-Inducing Peptides Using AI
August 16, 2018
- Intuniv Filed for Adult ADHD: Shionogi/Shire
August 16, 2018
- Astellas Snaps Up UK Gene Therapy Firm Quethera
August 10, 2018
- I/O in Lung Cancer - 1: US Merck Sweeping Frontline NSCLC Space with Keytruda
August 10, 2018
- Takeda Joins Liver-Focused Biotech Launch with US$100 Million Partnership
August 10, 2018
- JCR’s Sakigake-Designated Hunter Syndrome Treatment Enters Japan PIII Study
August 10, 2018
- Mogamulizumab Bags US Approval for Mycosis Fungoides, Sézary Syndrome: Kyowa Kirin
August 10, 2018
- As Rituxan Biosimilar Enjoys Solid Start, Sandoz Japan Chief Says It’s Important to Be First to Market
August 9, 2018
- Otsuka’s Half-Year Pharma Sales Up 4.1% on Global Brands
August 9, 2018
- Teijin Making Inroads into Biosimilar Arena with Sales Tie-Up for Enbrel Follow-On
August 9, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…